Remote digital care for adolescents with type 1 diabetes
Preliminary Study for the Evaluation of Teleduc-diab Additional Remote Digitalcare Effects in Adolescents With Poorly Controled Type 1 Diabetes
This study is testing a new remote care program to see if it can help teenagers with type 1 diabetes better manage their blood sugar levels.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 12 Years to 17 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT05421715 on ClinicalTrials.gov |
What this trial studies
This pilot study evaluates the effects of an experimental remote digital care program called TELEDUC-DIAB on adolescents with poorly controlled type 1 diabetes. The program includes personalized remote care from healthcare professionals, a monitoring platform, and a mobile application designed for patient education. Over six months, participants will receive enhanced support to improve their glycemic control alongside their conventional diabetes management. The study aims to document the impact of these digital tools on the health outcomes of adolescents with type 1 diabetes.
Who should consider this trial
Good fit: Ideal candidates are adolescents aged 12 to 18 with poorly controlled type 1 diabetes and a glycated hemoglobin level of 8% or higher.
Not a fit: Patients with other conditions that interfere with diabetes management or those without access to compatible digital media may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve glycemic control and overall diabetes management in adolescents.
How similar studies have performed: While some studies have explored digital tools for diabetes management, the specific combination of remote care and educational applications in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adolescent aged ≥12 and \<18, with primary type 1 diabetes detected for at least 12 months, treated with multi-injection insulin or insulin pump * Glycated hemoglobin greater than or equal to 8% for more than 3 months * Use a continuous interstitial glucose recording system (CGM) * Have at least one parent/guardian with a significant caregiver role in the management of the adolescent's diabetes (as determined by the investigator) participating in the study * Have digital media compatible with the digital applications of the TELEDUC- DIAB (Mobile phone and computer) Exclusion Criteria: • Other pathologies associated with diabetes which, according to the investigator, could interfere with glycemic control or the management of adolescent diabetes (examples: secondary diabetes, cystic fibrosis, Down syndrome; transplants, corticosteroid therapy, etc.)
Where this trial is running
Toulouse
- University Hospital TOULOUSE — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Maeva TALVARD, MD — University Hospital, Toulouse
- Study coordinator: Julie PELICAN, MD PhD
- Email: juliepelicand@gmail.com
- Phone: 05 67 77 13 39
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.